Profile data is unavailable for this security.
About the company
Medtronic plc is a global healthcare technology company. It develops, manufactures, and markets its medical devices and technologies to hospitals, physicians, clinicians, and patients. Its operating segments include Cardiovascular, Medical Surgical, Neuroscience and Diabetes. Cardiovascular products include pacemakers, insertable cardiac monitors, and cardiac resynchronization therapy devices. Medical Surgical products include patient care from diagnosis to recovery, with a focus on diseases of the gastrointestinal tract, lungs, pelvic region, kidneys, obesity, and preventable complications. Neuroscience products include various spinal implants, bone graft substitutes, biologic products, image-guided surgery and intra-operative imaging systems. Diabetes products include insulin pumps, continuous glucose monitoring (CGM) systems, consumables, and smart insulin pen systems. The Company also provides PROPEL and SINUVA, which is bioabsorbable, steroid-eluting implants for sinus patients.
- Revenue in USD (TTM)31.69bn
- Net income in USD5.04bn
- Incorporated2014
- Employees95.00k
- LocationMedtronic PLC20 On Hatch, Hatch Street LowerDUBLIN 2IrelandIRL
- Phone+353 14381700
- Websitehttps://www.medtronic.com/
More ▼
Mergers & acquisitions
| Acquired company | MDT:NYQ since announced | Transaction value |
|---|---|---|
| Cathworks Ltd | 6.37% | -- |
| Acutus Medical Inc-Left-Heart Access Portfolio | -11.39% | 87.00m |
| Affera Inc | -10.02% | -- |
| Triple Jump Israel Ltd | -25.93% | -- |
Data delayed at least 15 minutes, as of Aug 17 2022 14:45 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter International Inc | 14.19bn | 1.01bn | 29.69bn | 60.00k | 30.01 | 3.41 | 13.66 | 2.13 | 2.00 | 2.00 | 27.99 | 17.58 | 0.551 | 3.65 | 6.32 | 236,550.00 | 3.97 | 6.03 | 4.63 | 7.22 | 39.16 | 41.58 | 7.20 | 10.02 | 1.33 | 8.00 | 0.6521 | 38.31 | 9.52 | 4.70 | 16.52 | -23.70 | 0.6589 | 16.53 |
| DexCom, Inc. | 2.67bn | 199.70m | 33.42bn | 6.30k | 189.28 | 15.62 | 104.31 | 13.18 | 0.4741 | 0.4741 | 6.52 | 5.75 | 0.55 | 2.67 | 5.12 | 424,349.20 | 4.11 | 5.56 | 4.80 | 6.50 | 67.15 | 67.29 | 7.47 | 8.91 | 4.30 | 5.49 | 0.4735 | 0.00 | 27.08 | 33.69 | -68.66 | -- | 47.52 | -- |
| ResMed Inc. | 3.54bn | 779.48m | 34.64bn | 7.97k | 45.90 | 10.87 | 37.84 | 10.07 | 5.31 | 5.31 | 24.10 | 22.42 | 0.7459 | 2.69 | 6.60 | 444,101.90 | 16.43 | 11.98 | 19.62 | 14.03 | 56.29 | 57.66 | 22.02 | 17.49 | 1.56 | 33.08 | 0.1719 | 45.57 | 8.11 | 11.70 | -23.67 | 6.13 | 11.49 | 5.39 |
| Boston Scientific Corporation | 12.33bn | 828.00m | 58.74bn | 41.00k | 72.63 | 3.47 | 30.76 | 4.86 | 0.5763 | 0.5763 | 8.58 | 12.06 | 0.3892 | 2.44 | 6.86 | 300,707.30 | 2.79 | 3.26 | 3.19 | 4.00 | 68.48 | 69.40 | 7.16 | 8.03 | 0.8578 | 6.54 | 0.3421 | 0.00 | 19.92 | 7.23 | 956.52 | 23.20 | 1.75 | -- |
| Edwards Lifesciences Corp | 5.36bn | 1.46bn | 62.89bn | 15.70k | 44.94 | 10.83 | 40.47 | 12.02 | 2.31 | 2.31 | 8.50 | 9.59 | 0.6658 | 1.59 | 8.39 | 341,082.80 | 18.09 | 15.99 | 20.45 | 18.95 | 77.78 | 75.11 | 27.18 | 23.63 | 2.60 | -- | 0.0911 | 0.00 | 19.29 | 12.04 | 82.55 | 21.42 | 8.69 | -- |
| Becton Dickinson and Co | 19.24bn | 1.52bn | 72.81bn | 75.00k | 48.86 | 2.89 | 19.60 | 3.83 | 5.29 | 5.79 | 66.91 | 89.39 | 0.3579 | 3.46 | 8.96 | 256,586.70 | 3.00 | 2.61 | 3.48 | 2.96 | 45.14 | 46.63 | 8.38 | 7.49 | 0.9017 | 5.36 | 0.391 | 72.79 | 18.29 | 10.16 | 161.02 | 15.45 | 11.39 | 4.69 |
| Stryker Corporation | 17.63bn | 2.08bn | 81.32bn | 46.00k | 40.32 | 5.29 | 27.22 | 4.70 | 5.44 | 5.44 | 46.09 | 41.43 | 0.5056 | 1.73 | 6.02 | 383,239.10 | 5.96 | 6.73 | 6.81 | 7.95 | 64.85 | 65.57 | 11.79 | 13.16 | 1.15 | -- | 0.4605 | 42.39 | 19.21 | 8.60 | 24.70 | 3.90 | 1.39 | 11.20 |
| Intuitive Surgical, Inc. | 5.96bn | 1.43bn | 83.16bn | 9.79k | 60.76 | 7.06 | 46.90 | 14.24 | 3.91 | 3.91 | 16.28 | 33.67 | 0.4587 | 2.94 | 7.75 | 608,986.00 | 11.18 | 14.12 | 12.25 | 15.68 | 68.16 | 68.83 | 24.36 | 29.38 | 4.74 | -- | 0.00 | 0.00 | 31.01 | 16.10 | 60.72 | 18.22 | 45.67 | -- |
| Medtronic PLC | 31.69bn | 5.04bn | 123.70bn | 95.00k | 25.21 | 2.38 | 16.11 | 3.95 | 3.74 | 3.74 | 23.50 | 39.49 | 0.3443 | 2.23 | 5.75 | 333,536.80 | 5.50 | 5.08 | 6.22 | 5.72 | 68.53 | 68.46 | 15.97 | 15.45 | 1.49 | 17.00 | 0.3138 | 62.61 | 5.21 | 1.30 | 43.97 | 4.58 | 1.76 | 7.94 |
| Abbott Laboratories | 45.55bn | 8.55bn | 188.97bn | 113.00k | 22.92 | 5.29 | 16.19 | 4.24 | 4.81 | 4.81 | 25.62 | 20.84 | 0.6177 | 3.36 | 6.84 | 403,079.70 | 11.60 | 5.59 | 14.02 | 6.57 | 58.15 | 57.18 | 18.78 | 11.61 | 1.54 | 22.50 | 0.3134 | 63.22 | 24.47 | 15.61 | 57.24 | 46.08 | 10.95 | 11.60 |
| Thermo Fisher Scientific Inc. | 42.82bn | 7.44bn | 227.58bn | 130.00k | 31.51 | 5.49 | 22.04 | 5.42 | 18.80 | 18.80 | 108.20 | 107.95 | 0.5411 | 4.44 | 5.64 | 329,384.60 | 9.51 | 7.49 | 10.74 | 8.57 | 46.63 | 47.28 | 17.57 | 16.38 | 1.13 | 22.86 | 0.416 | 6.77 | 21.71 | 16.50 | 21.18 | 30.70 | 41.55 | 10.76 |
Data as of Aug 17 2022. Currency figures normalised to Medtronic PLC's reporting currency: US Dollar USD
31.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2022 | 117.42m | 8.84% |
| BlackRock Fund Advisorsas of 30 Jun 2022 | 66.57m | 5.01% |
| SSgA Funds Management, Inc.as of 31 Mar 2022 | 58.50m | 4.40% |
| Massachusetts Financial Services Co.as of 30 Jun 2022 | 37.46m | 2.82% |
| Wellington Management Co. LLPas of 31 Mar 2022 | 31.11m | 2.34% |
| Geode Capital Management LLCas of 30 Jun 2022 | 26.53m | 2.00% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2022 | 22.02m | 1.66% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2022 | 19.28m | 1.45% |
| Managed Account Advisors LLCas of 30 Jun 2022 | 17.75m | 1.34% |
| Lazard Asset Management LLCas of 30 Jun 2022 | 16.15m | 1.22% |
More ▼
Data from 31 Mar 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
